Gut microbial production of lithocholic acid reprograms pro-resolutive macrophages to enhance vedolizumab responsiveness via the TGR5/FXR–NF-κB axis
The ISME Journal · 14.01.2026 · 20 (1)
DOI: 10.1093/ismejo/wrag028 ↗Kurz gefasst
Fachartikel in der Zeitschrift The ISME Journal, online erschienen am 16.02.2026. Verfasst von Bing Han und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Medical Science and Technology Research Joint Venture Project, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Crohn’s disease (CD) is a complex chronic transmural inflammatory bowel disease. Although vedolizumab (VDZ) markedly improves clinical outcomes in CD, treatment non-response remains a significant limitation, constraining its broader utility. Elucidating the mechanisms underlying VDZ responsiveness is thus critically needed. In this research, we employed a humanized mouse model of 2,4,6-trinitrobenzene sulfonic acid–induced colitis to investigate VDZ treatment response in CD. Our findings indicate that VDZ significantly alleviated disease phenotypes in a portion of CD mice. Integrated metagenomic and metabolomic profiling identified baseline gut microbiota–derived secondary bile acids as potential predictors of VDZ efficacy. Subsequent fecal microbiota transplantation from clinical donors into pseudo-germ-free mice confirmed that gut microbial composition critically influences VDZ responsiveness. Targeted metabolomics further pinpointed lithocholic acid (LCA) as a key microbially derived metabolite correlated with therapeutic remission. Single-cell RNA sequencing also revealed that intestinal macrophages serve as pivotal mediators of LCA-driven modulation of treatment outcomes. Furthermore, transcriptomic analyses demonstrated that LCA polarizes macrophages toward an M2-resolutive phenotype via concurrent engagement of the TGR5/FXR and their downstream nuclear factor kappa-B (NF-κB) pathways. Ultimately, using a conditioned medium co-culture system, we established that the regulatory effects of pro-resolutive macrophage niche on treatment response in a manner dependent on the TGR5/FXR–NF-κB axis. Taken together, our study elucidates a microbiota-immune circuit in which gut microbial metabolite LCA augments VDZ responsiveness in CD by reprogramming macrophages toward a pro-resolutive phenotype via the TGR5/FXR–NF-κB signaling network. These insights provide a mechanistic foundation for biomarker development and personalized therapeutic strategies in inflammatory bowel disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230036, China.
- National Key Laboratory of Immune Response and Immunotherapy, University of Science and Technology of China, Hefei, 230026, China.
- Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
- Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
- Department of Clinical Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Förderung
- Henan Provincial Medical Science and Technology Research Joint Venture Project
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Guangxi Natural Science Foundation
- Key Project of Guangxi Natural Science Foundation
Zitieren
APA
Han, B., Wen, H., Li, Y., Wang, Y., Lv, X., Kang, M., Huang, W., Lan, Y., Tong, S., Zhang, M., Chen, D., Zhu, C., Jiang, Y., & Tang, D. (2026). Gut microbial production of lithocholic acid reprograms pro-resolutive macrophages to enhance vedolizumab responsiveness via the TGR5/FXR–NF-κB axis. The ISME Journal, 20(1). https://doi.org/10.1093/ismejo/wrag028
Vancouver
Han B, Wen H, Li Y, Wang Y, Lv X, Kang M, et al. Gut microbial production of lithocholic acid reprograms pro-resolutive macrophages to enhance vedolizumab responsiveness via the TGR5/FXR–NF-κB axis. The ISME Journal. 2026;20(1). doi:10.1093/ismejo/wrag028
BibTeX
@article{Han2026,
author = {Han, Bing and Wen, Hongtao and Li, Ya and Wang, Yucai and Lv, Xiaoping and Kang, Mei and Huang, Wei and Lan, Yining and Tong, Shilin and Zhang, Mengying and Chen, Deyi and Zhu, Chen and Jiang, Yong and Tang, Daiyuan},
title = {Gut microbial production of lithocholic acid reprograms pro-resolutive macrophages to enhance vedolizumab responsiveness via the TGR5/FXR–NF-κB axis},
journal = {The ISME Journal},
year = {2026},
volume = {20},
number = {1},
doi = {10.1093/ismejo/wrag028}
}
EUVIMED